Connect Biopharma (NASDAQ:CNTB) Announces Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Connect Biopharma (NASDAQ:CNTB – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), Zacks reports.

Connect Biopharma Stock Up 14.9%

Shares of Connect Biopharma stock opened at $0.67 on Thursday. The company has a market cap of $41.89 million, a P/E ratio of -0.58 and a beta of 0.06. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37. Connect Biopharma has a one year low of $0.55 and a one year high of $3.82. The firm has a fifty day moving average of $0.96 and a two-hundred day moving average of $2.08.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings lowered shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. BTIG Research decreased their target price on Connect Biopharma to $5.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Oppenheimer dropped their price objective on shares of Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. Leerink Partners started coverage on Connect Biopharma in a research note on Monday, October 12th. They set an “outperform” rating and a $4.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Connect Biopharma in a research report on Wednesday, October 28th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.88.

View Our Latest Analysis on CNTB

About Connect Biopharma

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

Featured Articles

Earnings History for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.